Public Employees Retirement System of Ohio bought a new position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 34,050 shares of the biotechnology company’s stock, valued at approximately $229,000.
Other hedge funds also recently added to or reduced their stakes in the company. Osaic Holdings Inc. increased its holdings in shares of Arcturus Therapeutics by 51.8% in the 2nd quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 738 shares during the period. BNP Paribas Financial Markets boosted its stake in Arcturus Therapeutics by 163.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 2,586 shares during the period. Mercer Global Advisors Inc. ADV bought a new position in Arcturus Therapeutics in the 4th quarter worth about $64,000. Intech Investment Management LLC bought a new position in Arcturus Therapeutics in the 4th quarter worth about $70,000. Finally, CANADA LIFE ASSURANCE Co increased its stake in shares of Arcturus Therapeutics by 65.1% in the fourth quarter. CANADA LIFE ASSURANCE Co now owns 12,009 shares of the biotechnology company’s stock valued at $73,000 after purchasing an additional 4,737 shares during the period. 94.54% of the stock is currently owned by institutional investors.
Arcturus Therapeutics Stock Up 5.4%
Shares of ARCT stock opened at $14.73 on Friday. The stock has a 50-day simple moving average of $9.57 and a 200 day simple moving average of $8.33. The stock has a market capitalization of $418.63 million, a P/E ratio of -4.45 and a beta of 2.48. Arcturus Therapeutics Holdings Inc. has a fifty-two week low of $5.50 and a fifty-two week high of $24.17.
Analyst Ratings Changes
A number of research analysts have recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcturus Therapeutics in a report on Friday, July 17th. Roth Capital reaffirmed a “buy” rating and issued a $41.00 price objective on shares of Arcturus Therapeutics in a report on Wednesday, September 2nd. Finally, Wall Street Zen upgraded shares of Arcturus Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, August 9th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Arcturus Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $23.00.
Get Our Latest Analysis on Arcturus Therapeutics
Arcturus Therapeutics Company Profile
Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.
The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.
Featured Stories
- Five stocks we like better than Arcturus Therapeutics
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Want to see what other hedge funds are holding ARCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report).
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
